Peer-reviewed article

Esketamine Nasal Spray versus Quetiapine for Resistant Depression.

The New England journal of medicineJan 1, 2024United Kingdom, Austria, France1 citationsDOI: 10.1056/nejmc2313230

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetamineDepression

View paper

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

This study's objects

Directly linked records, matched by DOI, trial reference, or registry, not just topic.

Registered trial(s)

TrialKetamine

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder

ClinicalTrials.gov2020

Related research

ArticleKetamine

Pharmacologic Approaches to Suicide Prevention.

Zisook S, Domingues I, Compton J

Europe PMC2023

ArticleKetamine

Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.

Drozdz SJ, Goel A, McGarr MW +6

Europe PMC2022

ArticleKetamine

Effects of ketamine on individual symptoms and symptom networks of depression in a randomised controlled trial of ketamine for treatment-resistant depression.

Hossein S, Rengasamy M, Uzamere A +5

Europe PMC2025